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Introduction. Despite improvements in radiotherapy techniques, a substantial percentage of prostate cancer patients treated
with external beam radiotherapy still suffer from clinically relevant radio-induced toxicity. Variability in radiotherapy response
is mainly due to dosimetric factors, additional treatments and patient characteristics. However, nowadays there is increasing
evidence supporting the heritability of this phenotype. Most studies attempting to unravel the genetic background of radio-
induced toxicity, following a candidate gene approach, have been unable to replicate previous ﬁndings.
Objective. We aimed to identify new loci associated with the development of radio-induced toxicity through a genome-wide
association approach. Methods Samples were obtained from 735 unselected Galician (NW Spain) prostate cancer patients treated
at the RadiationOncologyDepartment of the Clinical UniversityHospital of Santiago deCompostela from2006 to 2011 (RADIOGEN
study). Morbidity was prospectively documented using the Common Terminology Criteria for Adverse Events v3.0. Standardised
total average toxicity (STAT) score was derived to assess acute and late overall toxicity. Univariate analyses were performed by
linear regression by comparison of allele frequencies, and covariates, with overall acute or late STAT scores. Multivariate analyses
of overall acute and late toxicity included those covariates with univariate p-values lower than 0.05. Multivariate linear regression
residuals were calculated for each patient to quantify the non-accounted toxicity by the available covariates.
Results. Nineteen covariateswere included into themultivariatemodel for acute toxicity, while the late toxicitymodelwas deﬁned
by three covariates, being themost signiﬁcant the previous report of acute toxicity. After quality data assessment 552,597markers
were evaluated. From these, seven and eighteen loci showed p values lower that 1×10−5 for the development of acute and late
radio-induced toxicity, respectively.
Conclusions. We have identiﬁed new genetic loci associates with overall radiotherapy toxicity by using a genome wide association
design. These results must be replicated in an independent cohort to be validated.
http://dx.doi.org/10.1016/j.rpor.2013.03.819
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Objectives. The aim of this study is to assess the biochemical non-evidence of disease survival (bNEDs), disease free survival (DFS),
and overall survival (OS) rates, as well as, to identify some of prognostic factors associated with this outcomes in intermediate
risk prostate cancer patients in the context of a multi-institutional Spanish database (RECAP).
Materials/methods. Patient selectionwas accordingNCCN criteria and all of patientswere treatedwith external beam radiotherapy.
Related variables included age, PSA, Gleason score, cT stage, number of positive cores, Androgen Deprivation Therapy (ADT) and
external radiation dose.
Results. A total of 1878 patients were included. Median age was 71 years (range: 47–86). Mean initial PSA was 10.24ng/ml (range
6–20ng/ml). Clinical stage T1 and T2 was 35% and 65%, respectively. 25% had Gleason score 6 and 75% Gleason score 7. Median
radiation dose to prostate was 74Gy (range: 66–76Gy) and 76% of patients received ADT. With a median follow-up of 61 months,
the 5-year and 10-year bNEDs was 92% and 78% respectively, 96 and 89% DFS and 98% and 95% for OS. There were not grade 3 GI
or GU acute and late toxicity. Multivariate analysis to determine independent prognostic factors for biochemical control will be
presented after the last follow-up.
